Neal G. Koller
President & Chief Executive Officer
President & Chief Executive Officer
- 3724a Thomas Point Road
Annapolis, Maryland 21403
USA
Tel: +1 443 994 0101
Fax: +1 410 990 9817
nkoller@plurogen.com
| PluroGen Therapeutics, Inc. 503 Broadleaf Way Charlottesville, Virginia 22911 USA Tel: +1 443 994 0101 Fax: +1 410 990 9817 www.plurogen.com |
October 28,2008
RE: PluroGen Therapeutics, Inc. Investor Update: Q3 2008
Dear Investor
Within the 3rd quarter of 2008, PluroGen reached the notable milestone in the history of every company – we shipped
and invoiced our 1st commercial product. Of course, we made a number of additional important steps, summarized
below, concluding another very successful and progressive quarter.
We hope this update is informative and we would be pleased to answer any of your questions. Thanks for both your
interest and your investment.
Q3 2008 Investor Update
PluroGen Milestones and Accomplishment
Commercial Partner Activities and Product Development
Regulatory
Intellectual Property
Manufacturing
Funding
Best Regards,
Neal G. Koller
President & CEO
PluroGen Therapeutics, Inc.
RE: PluroGen Therapeutics, Inc. Investor Update: Q3 2008
Dear Investor
Within the 3rd quarter of 2008, PluroGen reached the notable milestone in the history of every company – we shipped
and invoiced our 1st commercial product. Of course, we made a number of additional important steps, summarized
below, concluding another very successful and progressive quarter.
We hope this update is informative and we would be pleased to answer any of your questions. Thanks for both your
interest and your investment.
Q3 2008 Investor Update
PluroGen Milestones and Accomplishment
Commercial Partner Activities and Product Development
- Welcare (First Distribution Agreement signed Q1 2008)
- PluroGen shipped and invoiced Welcare its first order for its skin and wound cleansing medical device
product - Initiated negotiation of distribution agreement for Italy for PluroGel™ Silver Sulfadiazine product line
- PNG Gerolymatos SA, (Letter of Intent Signed Q2 2008)
- Initiated negotiation of distribution agreement for Greece for PluroGel™ Silver Sulfadiazine product line
- Gerolymatos initiated market research studies in both China and Turkey for PluroGel™ Silver Sulfadiazine
product line
- Derma Sciences delivered the 3rd set of dressing samples for PluroGen review and market evaluation
- Received a Letter of Intent from a privately-owned skin care company to develop a specialty line of PluroGen
based products to sell through their 1,250 site retail network
Regulatory
- Aggressively pursuing medical device regulatory approval for PluroGel™ Silver Sulfadiazine
- Signed contracts to initiate final testing required for 510(k)
- Welcare EU medical device approval for our PluroGel™ ingredient targeted for submission Q4 2008
- Continue to maintain low expense, forward activity for drug approval for PluroGel™ Silver Sulfadiazine
- Advance preparation for any future drug claims we determine to pursue
Intellectual Property
- Converted provisional patent to a patent application and filed the PCT for the biological activity of our gel
technology
- Nationalized the filed PCT application for our antimicrobial nano technology
- Continue to explore licensing IP/technology rights to Dr. Katz’s adipose (fat derived) stem cells for wound healing
Manufacturing
- Completed initial draft of Quality Controls Manual
- Manufactured first lot of PluroGel™ 45 – 5 Concentrate for Welcare
- Extended search for manufacturing capacity to make PluroGel™ concentrate for Welcare and others
Funding
- Reached the minimum requirement for note conversion; proceeding to convert all notes to Series A Preferred
stock
- Received signed subscription agreements totaling $275, 000 of the $2.0 million to be raised in the Series A
Offering
- Continue to pursue institutional and private investors
Best Regards,
Neal G. Koller
President & CEO
PluroGen Therapeutics, Inc.